Scenarios that move ALT
Altimmune, Inc. - Common Stock
Scenarios that move ALT: 9 analyses, 3 positive, 6 negative.
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +28 · confidence medium · horizon immediate
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▲ · impact +51 · confidence medium · horizon immediate
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▼ · impact -38 · confidence low · horizon weeks
- · Lilly reports strong weight loss results for new drug — ▼ · impact -68 · confidence low · horizon immediate
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -37 · confidence medium · horizon weeks
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -24 · confidence medium · horizon weeks
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▼ · impact -74 · confidence low · horizon weeks
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +56 · confidence high · horizon immediate
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▼ · confidence medium